TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Neurotech International ( (AU:NTI) ).
Neurotech International announced that its lead product, NTI164, will be featured at the International Rett Syndrome Foundation Scientific Meeting. The presentations, led by Professor Carolyn Ellaway, will highlight the positive outcomes of NTI164 in treating Rett Syndrome, showcasing its potential impact on the treatment landscape for this condition. This event represents a significant opportunity for Neurotech to strengthen its position in the biopharmaceutical industry, particularly in the field of pediatric neurological disorders.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is known for its broad-spectrum oral cannabinoid drug therapy, NTI164, which has shown significant clinical benefits in trials for Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome. Neurotech is also exploring treatments for spastic cerebral palsy.
Average Trading Volume: 814,156
Technical Sentiment Signal: Sell
Current Market Cap: A$19.94M
Learn more about NTI stock on TipRanks’ Stock Analysis page.